Generate Biomedicines, Inc. (GENB)
| Market Cap | 1.97B |
| Revenue (ttm) | 26.48M +55.9% |
| Net Income | -268.67M |
| EPS | -3.28 |
| Shares Out | 128.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,354,944 |
| Open | 15.77 |
| Previous Close | 15.77 |
| Day's Range | 14.74 - 16.30 |
| 52-Week Range | 11.00 - 22.67 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 26.00 (+69.6%) |
| Earnings Date | Aug 6, 2026 |
About GENB
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for GENB stock is "Strong Buy." The 12-month stock price target is $26.0, which is an increase of 69.60% from the latest price.
News
Generate Biomedicines price target raised to $30 from $25 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Generate Biomedicines (GENB) to $30 from $25 and keeps a Buy rating on the shares. The GB-0895 data uphold six-month dosing, the…
Generate Biomedicines falls -16.7%
Generate Biomedicines (GENB) is down -16.7%, or -$3.41 to $16.97.
Generate Biomedicines falls -11.0%
Generate Biomedicines (GENB) is down -11.0%, or -$2.25 to $18.13.
Generate Biomedicines rises 17.7%
Generate Biomedicines (GENB) is up 17.7%, or $3.14 to $20.86.
Generate Biomedicines reports Q2 EPS (52c), consensus (49c)
Reports Q2 revenue $6.31M, consensus $5.3M. “Our team’s focus on execution for our clinical programs and translating our generative biology platform into the next generation of differentiated medicine...
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions Phase 1b data for GB-0895 in COPD to be p...
Generate Biomedicines Quarterly report: Q2 2026
Generate Biomedicines has published its Q2 2026 quarterly earnings report on August 6, 2026.
Generate Biomedicines Earnings release: Q2 2026
Generate Biomedicines released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Generate Biomedicines falls -9.5%
Generate Biomedicines (GENB) is down -9.5%, or -$1.50 to $14.22.
AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts
Newly Constructed Phase 2 now 100% Leased Further Solidifies Innovation Park as Boston's Premier Advanced Manufacturing Destination BOSTON, June 22, 2026 /PRNewswire/ -- IQHQ, Inc. today announced tha...
Generate Biomedicines Slides: Corporate presentation
Generate Biomedicines has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.
Generate Biomedicines Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The platform integrates advanced computational and experimental methods to accelerate novel protein drug discovery, with a lead anti-TSLP antibody in phase III for severe asthma and a robust oncology pipeline. Strategic partnerships and a focus on biannual dosing aim to improve compliance and market impact.
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
SOMERVILLE, Mass., May 28, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) today announced that it intends to participate in the Goldman Sachs Global Healthcare Conference on Monday, J...
Generate Biomedicines price target raised to $22 from $20 at Morgan Stanley
Morgan Stanley analyst Sean Laaman raised the firm’s price target on Generate Biomedicines (GENB) to $22 from $20 and keeps an Overweight rating on the shares.
Generate Biomedicines price target raised to $25 from $16 at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Generate Biomedicines (GENB) to $25 from $16 and keeps a Buy rating on the shares. The company’s GB-0895 is…
Generate Biomedicines Quarterly report: Q1 2026
Generate Biomedicines has published its Q1 2026 quarterly earnings report on May 7, 2026.
Generate Biomedicines Earnings release: Q1 2026
Generate Biomedicines released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Generate Biomedicines reports Q1 revenue $7.22M, consensus $4.75M
“We saw strong progress in the first quarter across our clinical pipeline, next generation of therapeutic programs, and advancing our platform,” said Mike Nally, chief executive officer of Generate Bi...
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update
SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in mid-202...
Generate Biomedicines initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Generate Biomedicines (GENB) with a Buy rating and $16 price target The stock has fallen over 20% even as GB-0895 advanced into…
Generate Biomedicines Slides: Corporate presentation
Generate Biomedicines has posted slides in relation to its latest quarterly earnings report, which was published on April 8, 2026.
Generate Biomedicines initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Eric Schmidt initiated coverage of Generate Biomedicines (GENB) with an Overweight rating. Generate is developing GB-0895, a long-acting anti-TSLP antibody for asthma and COP...
Generate Biomedicines initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Eric Schmidt initiated coverage of Generate Biomedicines (GENB) with an Overweight rating.
Generate Biomedicines initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Generate Biomedicines (GENB) with a Buy rating and $30 price target The firm has “high conviction in multi-blockbuster sales” for Generate’s Phase 3 long-acting thymic...
Generate Biomedicines initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Sean Laaman initiated coverage of Generate Biomedicines (GENB) with an Overweight rating and $20 price target The firm says its investment thesis is centered on GB-0895, the…